



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 121 936 A1**

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:
08.08.2001 Bulletin 2001/32

(51) Int Cl.7: **A61K 38/17, A61K 38/22**

(21) Application number: **99943391.5**

(86) International application number:
PCT/JP99/05080

(22) Date of filing: **17.09.1999**

(87) International publication number:
WO 00/16795 (30.03.2000 Gazette 2000/13)

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB IE IT LI LU NL SE

(30) Priority: **17.09.1998 JP 26300498**

(71) Applicant: **SNOW BRAND MILK PRODUCTS, CO., LTD.**
Sapporo-shi Hokkaido 065-0043 (JP)

(72) Inventors:
• **GOTO, Masaaki**
Ishibashi-machi, Shimotsuga-gun, Tochigi (JP)
• **TOMOYASU, Akihiro**
Shimotsuga-gun, Tochigi 329-0519 (JP)

• **YAMAGUCHI, Kyoji**
Omiya-shi, Saitama 330-0006 (JP)
• **KINOSAKI, Masahiko**
Kawachi-gun, Tochigi 329-0528 (JP)
• **NAKAGAWA, Nobuaki, Heights Sakae E201**
Shimotsuga-gun, Tochigi 329-0415 (JP)

(74) Representative:
Forstmeyer, Dietmar, Dr. rer. nat., Dipl.-Chem. et al
Boeters & Bauer,
Bereiteranger 15
81541 München (DE)

(54) **PREVENTIVES AND/OR REMEDIES FOR OBESITY**

(57) To provide a novel preventive and/or therapeutic agent for obesity.

The preventive and/or therapeutic agent for obesity contains as an active ingredient stanniocalcin.

The preventive and/or therapeutic agent of the present invention has an excellent activity of inhibiting the differentiation and maturation of adipocytes, thereby being useful as a drug for preventing and/or treating obesity.

EP 1 121 936 A1

D scriptionTechnical Field

[0001] The present invention relates to a novel preventive and/or therapeutic for obesity.

[0002] A pharmaceutical preparation of the present invention has excellent preventive and/or therapeutic effects, for obesity and is useful as a pharmaceutical.

Background Art

[0003] Obesity is a risk factor of diseases such as diabetes mellitus, hypertonia, and heart disease, which threaten health of people in advanced countries. Obesity means physical conditions wherein adipose tissues have abnormally accumulated. Adipose tissues are special organs wherein surplus in vivo energies are stored as fat or triglyceride, and constructed of fibroblasts including adipocytes and their precursors, macrophages, blood vessel surrounding cells, blood cells, and the like.

[0004] Adipocytes are said to amount from 1/3 to 2/3 of cells which are present in adipose tissues and to accumulate fats or triglycerides therein. Adipocytes differentiate and mature through the process starting from mesenchymal multipotent stem cells, and growing into lipoblasts which have acquired a base as adipocytes, precursor adipocytes with no lipid droplets but having initial markers of adipocytes, immaturated adipocytes containing lipid droplets, and finally into matured adipocytes containing a large quantity of accumulated fats. Adipocytes of adults suffering from slight obesity hypertrophically grow due to increase in the amount of accumulated triglyceride. Number of adipocytes increases as the degree of obesity becomes conspicuous. Therefore, decreasing the number of adipocytes by controlling differentiation and maturation or suppressing hypertrophia of matured adipocytes are expected to stop progress of obesity by suppressing the increase in the amount of accumulated fats, and to treat obesity. Control of in vivo adipocyte differentiation has been proven to undergo either positively or negatively according to a number of factors derived from environmental factors such as ingestion, exercise, and so on. As cytokines which control differentiation of adipocytes from adipocyte precursors, tumor necrosis factor- α (TNF- α : Torti F. M. et al., Science, Vol. 229, p 867 (1985)), transforming growth factor- β (Ignotz R. A. et al., Proc. Natl. Acad. Sci. USA, Vol. 82, p 8530 (1985)), preadipocyte factor-1 (Pref-1: Smas C.M. et al., Cell, Vol. 73, p 725 (1993)), and the like have been reported. In addition, leptin, the translational product of an ob gene which has recently been cloned, has been reported to possibly decrease the intake amount and the weight of adipose tissues via central nerve system (Levin N. et al. Proc. Natl. Acad. Sci. USA, Vol. 93, P 1726, 1996).

[0005] Furthermore, intracerebral peptide-neuropeptide Y which exhibits a strong appetite stimulating effect and its receptor are gathering attention as materials for the development of an obesity suppressing pharmaceutical (Sainsburg A. et al, Diabetologia, Vol.39, p353, 1996). These cytokines are expected to become a therapeutic agent for obesity due to their adipocyte depressing action on accumulation of fat. Clinical tests as an obesity therapeutic or preventive agent is ongoing on some of these cytokines such as leptin.

[0006] At present, one obesity therapeutic or preventive agent is commercially available in the USA under the ReduxTM (American Home Products Co.). Other drugs such as Meridia (Kunol Co.) and Xenical (Roche Co.) will be approved as an obesity treating agent or a fat absorption inhibitor in the USA. The treatments method using these pharmaceuticals, however, are not necessarily satisfactory in the effects and therapeutic results. Development of a new agent which is available exhibits for these pharmaceuticals higher curative effect and less side effect usable have been desired.

Disclosure of the Invention

[0007] In view of the above circumstances, the present inventors have intensive investigated a substance which shows anti-obesity activity or obesity-curing activity, and as a result, found that stanniocalcin (STC: Olsen H.S. et al., Proc. Natl. Acad. Sci. USA, vol. 93, p 1792 (1996)) which is known as a protein controlling metabolism of minerals, exhibits adipogenesis inhibitory activity, or inhibitory activity of differentiation and/or maturation of adipocytes, which physiologic activity has not been expected of stanniocalcin at all in the past. Accordingly, the object of the present invention is to provide a preventive and/or therapeutical agent for obesity containing a novel substance as an effective ingredient. The present invention relates to a preventive and/or therapeutical agent for obesity, which contains stanniocalcin as an effective ingredient. The pharmaceutical preparation according to the present invention can exhibit excellent preventive and/or therapeutic agent effects for obesity and are useful as a pharmaceutical.

[0008] Stanniocalcin was discovered in fishes at first and was subsequently clarified to exist in mammals including humans. Then, cDNA of human embryo was isolated by the genetic engineering procedure on the basis of structural similarity. Human stanniocalcin can be obtained by expressing the resultant cDNA in a variety of cells using the genetic

engineering technique.

[0009] It has been well known that stanniocalcin reduces a calcium level *in vivo* when given to fishes, and also inhibits phosphate excretion to urine when administered to rats (Proc. Natl. Aca. Sci. USA., 93, 1792 (1996)). However, stanniocalcin has not been known to possess excellent preventive and therapeutic effects for obesity.

The Best Mode for Carrying out the Invention

[0010] Stanniocalcin, or the effective ingredient according to the present invention, can be obtained by the method of Olsen H. S. et al. (Proc. Natl. Acad. Sci. USA, vol. 93, p 1792 (1996)). Specifically, the above-described literature reference or gene bank or the like can be searched to learn the sequence of cDNA of stanniocalcin, and based on the sequence information, stanniocalcin cDNA can be obtained using the PCR method etc.. Stanniocalcin expression cells can be obtained by transfections of the expression vector into animal cells etc., the said expression vector is obtained by insertion of the resultant cDNA. Then, stanniocalcin can be obtained by cultivating the resultant stanniocalcin expression cells, followed by purification of the resultant culture solution by conventionally employed procedures. The adipogenesis inhibitory activity can be determined by estimating the suppression effects of adipogenesis induced by dexamethasone with retardation of triglyceride accumulation using mouse preadipocytic cell as a target according to the method of Kodama H. et al. (Journal of Cellular Physiology, Vol. 112, p83 (1982)),

[0011] Stanniocalcin, or the effective ingredient of the present invention, can be safely administered to human being and animals in the form of pharmaceutical compositions intended for use in the prevention and/or treatment of obesity. Stanniocalcin can be made into pharmaceutical preparations and administered either for orally or parenterally. Examples of the pharmaceutical composition include compositions for injection, compositions for dripping, suppositories, nasal agent, sublingual agent, percutaneous absorption agent, and the like. These pharmaceutical preparations are formulated according to known pharmaceutical preparation methods using pharmaceutically acceptable carriers, excipients, stabilizers, coloring matters, surfactants and other additives, and made into target preparations. In the case of compositions for injection, a pharmacologically effective amount of stanniocalcin, which is the effective ingredient of the present invention, may be mixed with pharmaceutically acceptable excipients/activators, such as amino acids, sugars, cellulose derivatives and other organic/inorganic compounds, which may be generally added to compositions for injection. If necessary, pH adjusting agents, buffer agents, stabilizers, solubilizing agents, etc. may be added to thereby make a variety of injectable solutions in accordance with the conventional procedures.

[0012] Administration thereof is normally done to human adults at a daily dose of 10 µg to 10 mg/kg body weight, as divided in several times, either orally or parenterally. The particularly preferred dosage form is intravenous administration.

Example

[0013] Examples given in the below describe the present invention in more detail, whereby these examples are merely illustrative, and the present invention is in no way understood to be limited by them.

Example 1

Production of stanniocalcin

i) Isolation of poly(A)+ RNA from IMR-90 cells (pulmonary fibroblasts of human embryo, ATCC CCL-186)

[0014] About 10 µg of poly(A)+ RNA was isolated from 1×10^8 of IMR-90 cells using Fast Track mRNA Isolation Kit (Invitrogen Inc.) according to the protocol of Invitrogen Inc..

ii) Construction of human stanniocalcin expression vector

[0015] A single-stranded cDNA was synthesized using SuperScript II cDNA synthesis Kit (Gibco BRL Inc.) and 1 µg of the isolated poly(A)+ RNA used as a template, according to the protocol of Gibco BRL Inc.. Stanniocalcin (STC) cDNA: fragment was obtained by carrying out PCR using the obtained cDNA template and primer STCFIN (Sequence Identification No. 1) and primer STCRIXh (Sequence Identification No. 2) as designed according to the nucleotide sequence of human stanniocalcin. The composition for PCR solution is as follows:

10X Ex Taq Buffer (Takara Shuzo Co.)	10 µl
2.5 mM dNTP	8 µl

(continued)

cDNA solution	1 μ l
Ex Taq (Takara Shuzo Co.)	0.5 μ l
Distilled water	74.5 μ l
20 μ M Primer STCFIN	5 μ l
100 μ M Primer STCRIXh	1 μ l

[0016] The above-described solutions were mixed in a microcentrifugal tube, and PCR was performed under the following conditions: after pretreatment at 95°C for 3 min, the reaction of the three steps of at 95°C for 30 sec, at 55°C for 30 sec and at 72°C for 2 min was repeated 30 times. Then, the reaction mixture incubated at 70°C for 5 min. A portion of the reaction mixture was subjected to agarose gel electrophoresis, and a uniform DNA fragment of about 900 bp was identified. The fragment was sequenced by the conventional method, and it was confirmed to obtain the cDNA encoding stanniocalcin gene. The cDNA sequence and the amino acid sequence are shown in Sequence Identification Nos. 3 and 4, of sequence table respectively.

[0017] The resultant DNA fragment of about 900 bp was purified using QIAEXII DNA extraction kit (QIAGEN Inc.), and the purified DNA was cleaved by restriction enzymes XhoI and NheI (Takara Shuzo Co.) and purified using QIAEXII DNA extraction kit (STC XhoI-NheI fragment). Plasmid pCEPSTC which contained DNA encoding stanniocalcin gene was obtained by ligating the STC XhoI-NheI fragment to pCEP4 (Invitrogen Inc.) cleaved by restriction enzymes XhoI and NheI by ligation kit ver. 2 (Takara Shuzo Co.). *E. coli* (DH5 α ; Gibco BRL Inc.) containing the plasmid has been deposited, in the name of DH5 α /pCEP-STC and under Accession No. FERM BP-6736 in National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, The Ministry of International Trade and Industry, located at 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan (postal code 305-8566) on May 31, 1999. No erroneous uptake of bases in the DNA portion derived from PCR during the DNA synthesis was meanwhile confirmed by DNA sequencing.

iii) Expression of human stanniocalcin

[0018] *E. coli* DH5 α having pCEPSTC as obtained in Example 1-ii) was cultivated with shaking in 2 ml of Terific Broth (Life Technologies Inc.) containing 50 μ g/ml of ampicillin (Sigma Inc.) and 4.7 % of glycerol overnight at 37°C, and the plasmid DNA was purified from the bacterial cells using QIAWELL kit (QIAGEN Inc.). 293-EBNA cells (Invitrogen Inc.) in IMDM (Life Technologies Inc.) containing 10 % of fetal bovine serum were seeded in each well of a 24-well plate to 2×10^5 /well/ml, followed by cultivation in a CO₂ incubator (5 % CO₂) at 37°C overnight. pCEPSTC or pCEP4 was transfected to 293-EBNA cells using Fugene 6 (Behringer Mannheim Co.). DNA and Fugene 6 were used in portions of 0.5 μ g and 1 μ l, respectively. After transfection, the transfected cells were cultivated in a CO₂ incubator (5 % CO₂) at 37°C for 3 days. The resultant culture solution was assayed for adipogenesis inhibitory activity by the below-described procedure.

iv) Determination of adipogenesis inhibitory activity

[0019] Adipogenesis inhibitory activity was determined by the following procedure according to the method of Kodama H. et al. (Journal of Cellular Physiology, Vol. 112, p 83 (1982)): that is, using mouse pre-adipocytic cell strain MC3T3-G2/PA6 (RIKEN GENE BANK, RCB1127) as a target cell, the adipogenesis induced by dexamethasone was determined with triglyceride accumulation as an index of its inhibitory activity. The culture solution from the sample (Example 1-iii)) diluted with α -MEM (Gibco BRL Inc.) containing 10 % of fetal bovine serum, the culture solution of cells having the vector alone transfected, and the culture solution of pure 293-EBNA cells were distributed in each portion of 50 μ l into 96-well microplate, respectively, and 3×10^3 cells of pre-adipocytic cell strain MC3T3-G2/PA6 after being suspended in 50 μ l of α -MEM containing 2×10^{-7} M of dexamethasone and 10 % of fetal bovine serum were seeded, followed cultivation at 5% CO₂, 37°C and 100% humidity for one week. After cultivation for 7 days, the culture medium was removed by aspiration, then air-dried and assayed for the triglyceride accumulated in adipocytes with use of a triglyceride measuring kit (Triglyceride G-Test Wako, Code No. 274-69802, Wako Pure Chemicals Ind. Co.). The decreases at OD 510 nm were used for assessment of adipogenesis inhibitory activity. The obtained results are shown in Table 1. As the result, stanniocalcin in the resultant culture solution was confirmed to exhibit adipogenesis inhibitory activity.

Table 1:

Dilution	1/4	1/8	1/16	1/32
Culture solution of STC gene-transfected cells	0.061	0.060	0.057	0.054
Culture solution of vector-transfected cells	0.036	0.021	0.009	0.007
Culture solution of 293-EBNA cells	0.032	0.017	0.014	0.011

Example 2Determination of adipogenesis inhibitory activity using cells of mouse preadipocytic cell strain 3T3/L1

[0020] Using mouse pre-adipocytic cell strain 3T3-L1 (deposited at ATCC-Accession No. CL173) as a target, the formation of adipocytes induced by dexamethasone and 1-methyl-3-isobutylxanthine was measured by means of triglyceride accumulation, to determine the suppressing activity against adipocyte formation. Specifically, 50 μ l of a sample equivalent to the one in Example 1 diluted with α -MEM (Gibco BRL Inc.) containing 10 % of fetal bovine serum was placed into a 96-well microplate, and 5×10^3 cells of mouse preadipocyte 3T3-L1 were suspended in 50 μ l of α -MEM containing 4×10^{-7} M of dexamethasone, 2×10^{-5} M of 1-methyl-3-isobutylxanthine and 10 % of fetal bovine serum and then seeded, followed by cultivation at 5% CO₂, 37°C and 100% humidity for one week. After cultivation for 7 days, the culture medium was removed by aspiration, and the cells were air-dried to measure the triglyceride accumulated in adipocytes using a triglyceride assay kit (Triglyceride G-Test Wako, Code No. 274-69802, Wako Pure Chemicals Ind. Co.). The decrease of OD at 510 nm was taken as adipogenesis inhibitory activity. The obtained results are shown in Table 2. As a result stanniocalcin in the culture solution was confirmed to exhibit adipogenesis inhibitory activity, as in Example 1, when 3T3-L1 cells are used as a target.

Table 2:

Dilution	1/4	1/8	1/16	1/32
Culture solution of STC gene-transfected cells	0.081	0.083	0.082	0.083
Culture solution of vector-transfected cells	0.026	0.017	0.012	0.011
Culture solution of 293-EBNA cells	0.021	0.004	0.006	0.016

Example 3

Pharmaceutical Preparation Examples

Pharmaceutical Preparation Example 1: Production of Injection preparation

[0021] One mg of stanniocalcin obtained in Example 1 and 50 mg of human serum albumin were dissolved in 100 ml of 0.01M phosphate buffer solution (PBS, pH 7.0), and the solution was sterilized, divided into vials (2 ml each), lyophilized and sealed.

[0022] Pharmaceutical Preparation Example 2: Production of Injection preparation.

[0023] Fifty mg of stanniocalcin obtained in Example 1, 1 mg of Tween 80 and 50 mg of human serum albumin were dissolved in 100 ml of 0.01M phosphate buffer solution (PBS, pH 7.0), and the solution was sterilized, divided into vials (2 ml each), lyophilized and sealed.

Pharmaceutical Preparation Example 3: Production of Injection preparation.

[0024] One hundred mg of stanniocalcin obtained in Example 1, 50 mg of human serum albumin and 4 g of sorbitol were dissolved in 20 ml of 0.01M phosphate buffer solution (PBS, pH 7.0), and the solution was sterilized, divided into vials, lyophilized and sealed.

Industrial Applicability

[0025] According to the present invention, there is provided a novel preventive and/or therapeutic for obesity, which contains stanniocalcin as an effective ingredient. The pharmaceutical preparation of the present invention can exhibit excellent preventive and/or therapeutic effects against obesity and is useful as a pharmaceutical.

Reference to the Deposited Microorganisms

[0026]

- 5 a. Name and address of the Depositary organization in which the relevant microorganisms were deposited:
- Name: National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology,
 The Ministry of International Trade and Industry
- Address: 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan (postal code 305-8566)
- 10 b. The date when deposit was made with the organization of a. May 31, 1999 (as transferred from Bikoken No. P-16933, which was deposited on August 11, 1998).
- c. Accession Number attached to the deposit by the organization of a. FERM BP-6736
- 15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

5

<110> Snow Brand Milk Products Co., Ltd.

10

<120> Preventive and/or therapeutic for obesity

15

<130> SNOW-128

20

<160> 4

<210> 1

25

<211> 29

<212> DNA

30

<213> Artificial Sequence

<220>

35

<223> Description of Artificial Sequence: Synthesized DNA

40

<400> 1

GGGGCTAGCC AACAACTTAG CGGAAACTT

29

45

<210> 2

<211> 29

50

<212> DNA

<213> Artificial Sequence

55

<220>

5 <223> Description of Artificial Sequence: Synthesized DNA.

<400> 2

10 CCCCTCGAGT GTGTCAACAC CCCTAAAAT

29

15 <210> 3

<211> 741

20 <212> DNA

<213> Human

25 <300>

<301> Olsen H. S. et al.

30 <302> Human stanniocalcin : a possible hormonal regulator of
mineral metabolism.

<303> Proc. Natl. Acad. Sci. USA

35 <304> 93

<305> 5

40 <306> 1792

<307> 1996-03-05

45 <308> GenBank, U46768

<309> 1996-02-22

50 <400> 3

atgctccaaa actcagcagt gcttctgggtg ctggtgatca gtgcttctgc aacccatgag 60

55 gcggagcaga atgactctgt gagccccagg aaatcccagag tggcggccca aaactcagct 120

gaagtgggttc gttgcctcaa cagtgtctcta cagggtcggct gcggggcitt tgcatgcctg 180
5 gaaaactcca cctgtgacac agatgggatg tatgacatct gtaaatacctt cttgtacagc 240
gctgctaaat ttgacactca gggaaaagca ttcgtcaaag agagcttaaa atgcatcgcc 300
aacgggggtca cctccaaggt ctccctcgcc attcggaggt gctccacttt ccaaaggatg 360
10 attgctgagg tgcaggaaga gtgctacagc aagctgaatg tgtgcagcat cgccaagcgg 420
aaccctgaag ccatactga ggtcgtccag ctgcccaatc acttctccaa cagatactat 480
15 aacagacttg tccgaagcct gctggaatgt gatgaagaca cagtcagcac aatcagagac 540
agcctgatgg agaaaattgg gcctaacatg gccagcctct tccacatcct gcagacagac 600
cactgtgccc aaacacaccc acgagctgac ttcaacagga gacgcaccaa tgagccgcag 660
20 aagctgaaag tcctcctcag gaacctccga ggtgaggagg actctccctc ccacatcaaa 720
cgcacatccc atgagagtgc a 741

25

<210> 4

30

<211> 247

<212> PRT

<213> Human

35

<300>

40

<301> Olsen H. S. et al.

<302> Human stanniocalcin : a possible hormonal regulator of mineral me-
tabolism.

45

<303> Proc. Natl. Acad. Sci. USA

<304> 93

50

<305> 5

<306> 1792

<307> 1996-03-05

55

<400> 4

5 Met Leu Gln Asn Ser Ala Val Leu Leu Val Leu Val Ile Ser Ala Ser
 5 10 15
 10 Ala Thr His Glu Ala Glu Gln Asn Asp Ser Val Ser Pro Arg Lys Ser
 20 25 30
 15 Arg Val Ala Ala Gln Asn Ser Ala Glu Val Val Arg Cys Leu Asn Ser
 35 40 45
 20 Ala Leu Gln Val Gly Cys Gly Ala Phe Ala Cys Leu Glu Asn Ser Thr
 50 55 60
 25 Cys Asp Thr Asp Gly Met Tyr Asp Ile Cys Lys Ser Phe Leu Tyr Ser
 65 70 75 80
 30 Ala Ala Lys Phe Asp Thr Gln Gly Lys Ala Phe Val Lys Glu Ser Leu
 85 90 95
 35 Lys Cys Ile Ala Asn Gly Val Thr Ser Lys Val Phe Leu Ala Ile Arg
 100 105 110
 40 Arg Cys Ser Thr Phe Gln Arg Met Ile Ala Glu Val Gln Glu Glu Cys
 115 120 125
 45 Tyr Ser Lys Leu Asn Val Cys Ser Ile Ala Lys Arg Asn Pro Glu Ala
 130 135 140
 50 Ile Thr Glu Val Val Gln Leu Pro Asn His Phe Ser Asn Arg Tyr Tyr
 145 150 155 160
 55 Asn Arg Leu Val Arg Ser Leu Leu Glu Cys Asp Glu Asp Thr Val Ser
 165 170 175
 Thr Ile Arg Asp Ser Leu Met Glu Lys Ile Gly Pro Asn Met Ala Ser
 180 185 190

5 Leu Ph His Ile Leu Gln Thr Asp His Cys Ala Gln Thr His Pro Arg
 195 200 205
 10 Ala Asp Phe Asn Arg Arg Arg Thr Asn Glu Pro Gln Lys Leu Lys Val
 210 215 220
 15 Leu Leu Arg Asn Leu Arg Gly Glu Glu Asp Ser Pro Ser His Ile Lys
 225 230 235 240
 Arg Thr Ser His Glu Ser Ala
 245

Claims

1. A preventive and/or therapeutic agent for obesity which contains stanniocalcin as an effective ingredient.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/05080

A. CLASSIFICATION OF SUBJECT MATTER IntC16 A61K38/17, A61K38/22		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IntC16 A61K38/17, A61K38/22		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS, MEDLINE, Genbank/EMBL/DDBJ/GeneSeq		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO, 95/24411, A1 (HUMAN GENOME SCIENCES, INC.), 14 September, 1995 (14.09.95), Full text & JP, 9-511140, A & US, 5837498, A & US, 5877290, A & EP, 750626, A1	1
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 10 December, 1999 (10.12.99)		Date of mailing of the international search report 21 December, 1999 (21.12.99)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)